You are here

Shire

Shire says trial shows new HAE drug significantly reduces attacks

Shire says trial shows new HAE drug significantly reduces attacks

Reuters

clinical trials

hereditary angiodema

Flag link:

Allergan-Restasis Patent Battle Could Test Lawmakers' Resolve

Allergan-Restasis Patent Battle Could Test Lawmakers' Resolve

NY Shock Exchange

Teva Pharmaceutical

Flag link:

Shire defends record as UBS cuts price target on staff satisfaction reviews

Shire defends record as UBS cuts price target on staff satisfaction reviews

Reuters

Flag link:

Shire announces availability of MYDAYIS(TM) for ADHD treatment in the U.S.

Shire announces availability of MYDAYIS(TM) for ADHD treatment in the U.S.

Seeking Alpha

Flag link:

Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab

Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab

Endpoints

Flag link:

Shire hints at ADHD spinoff, but could someone step in and buy the neuro franchise?

Shire hints at ADHD spinoff, but could someone step in and buy the neuro franchise?

Fierce Pharma

Flag link:

Shire plots an ADHD public spinoff as CEO Ornskov completes a top-to-bottom overhaul

Shire plots an ADHD public spinoff as CEO Ornskov completes a top-to-bottom overhaul

Endpoints

Flemming Ornskov

Flag link:

Shire increasingly vulnerable to takeover attempts by big pharma companies

Shire increasingly vulnerable to takeover attempts by big pharma companies

GoInPharma

Flag link:

5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings

5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings

Yahoo/Zacks.com

Gilead Sciences

Flag link:

Shire blasts rival Roche for its “misleading” case for hemophilia trailblazer emicizumab

Shire blasts rival Roche for its “misleading” case for hemophilia trailblazer emicizumab

Motley Fool

Flag link:

Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul

Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul

Bloomberg

healthcare reform

Jazz Pharmaceuticals

Vertex Pharmaceuticals

Flag link:

Shire will cut U.S. locations and move HQ in consolidation push

Shire will cut U.S. locations and move HQ in consolidation push

Fierce Biotech

Flag link:

Shire’s Ornskov dictates another big revamp, with R&D/HQ moving into Cambridge

Shire’s Ornskov dictates another big revamp, with R&D/HQ moving into Cambridge

Endpoints

Flemming Ornskov

Flag link:

Pfizer Fueling Growth Of Competitors' Pipelines

Pfizer Fueling Growth Of Competitors' Pipelines

Forbes

Clovis Oncology

Puma Biotechnology

Flag link:

FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire

FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire

Endpoints

hereditary angiodema

Flag link:

A decade behind schedule, Shire finally gets an FDA OK for long-acting ADHD drug

A decade behind schedule, Shire finally gets an FDA OK for long-acting ADHD drug

Endpoints

Flag link:

Kamada slumps after Shire hands back rights

Kamada slumps after Shire hands back rights

BioPharma Dive

alpha-1 antitrypsin

graft vs host disease

Flag link:

Shire Is Poised To Dominate The HAE Market After Strong Phase III Data For SHP643

Shire Is Poised To Dominate The HAE Market After Strong Phase III Data For SHP643

Seeking Alpha

Flag link:

Shire writes off a shot at long-acting hemophilia drug after small study flops

Shire writes off a shot at long-acting hemophilia drug after small study flops

Endpoints

Xenetic Biosciences

clinical trials

Flag link:

Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application

Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application

Endpoints

Flag link: